Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 480

1.

Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study.

Pascual JC, Soler J, Puigdemont D, Pérez-Egea R, Tiana T, Alvarez E, Pérez V.

J Clin Psychiatry. 2008 Apr;69(4):603-8.

PMID:
18251623
2.

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.

Keck PE Jr, Reeves KR, Harrigan EP; Ziprasidone Study Group..

J Clin Psychopharmacol. 2001 Feb;21(1):27-35.

PMID:
11199944
3.

Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.

Potkin SG, Keck PE Jr, Segal S, Ice K, English P.

J Clin Psychopharmacol. 2005 Aug;25(4):301-10.

PMID:
16012271
4.

A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.

Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M.

J Clin Psychiatry. 2012 Dec;73(12):1541-7. doi: 10.4088/JCP.12m07670.

PMID:
23290327
5.

Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study.

Bellino S, Paradiso E, Bogetto F.

J Clin Psychiatry. 2006 Jul;67(7):1042-6.

PMID:
16889446
6.

Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania.

Keck PE Jr, Versiani M, Warrington L, Loebel AD, Horne RL.

J Clin Psychiatry. 2009 Jun;70(6):844-51.

PMID:
19573482
7.

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.

Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M.

J Clin Psychiatry. 2010 Feb;71(2):130-7. doi: 10.4088/JCP.09m05482yel.

PMID:
20122373
8.

A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.

Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, Merkatz L, Stein DJ.

J Clin Psychiatry. 2001 Mar;62(3):199-203.

PMID:
11305707
9.

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.

Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR.

Psychopharmacology (Berl). 1998 Nov;140(2):173-84.

PMID:
9860108
10.

Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.

Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B.

J Clin Psychiatry. 2011 Oct;72(10):1413-22. doi: 10.4088/JCP.09m05934.

PMID:
21672493
11.

Ziprasidone monotherapy in bipolar II depression: an open trial.

Liebowitz MR, Salmán E, Mech A, Dunner D, Johnson AE, Akhtar J, Pratap R.

J Affect Disord. 2009 Nov;118(1-3):205-8. doi: 10.1016/j.jad.2009.01.022.

PMID:
19264363
13.

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

Olié JP, Spina E, Murray S, Yang R.

Int Clin Psychopharmacol. 2006 May;21(3):143-51.

PMID:
16528136
14.

Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.

Lawson WB, Herman BK, Loebel A, Lazariciu I, Malik M.

CNS Spectr. 2009 Sep;14(9):478-86.

PMID:
19890230
15.

Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study.

Lohoff FW, Etemad B, Mandos LA, Gallop R, Rickels K.

J Clin Psychopharmacol. 2010 Apr;30(2):185-9. doi: 10.1097/JCP.0b013e3181d21951.

PMID:
20520293
16.

Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?

Lombardo I, Sachs G, Kolluri S, Kremer C, Yang R.

J Clin Psychopharmacol. 2012 Aug;32(4):470-8. doi: 10.1097/JCP.0b013e31825ccde5.

PMID:
22722504
17.
18.
19.

Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase.

Dell'Osso B, Hadley S, Allen A, Baker B, Chaplin WF, Hollander E.

J Clin Psychiatry. 2008 Mar;69(3):452-6.

PMID:
18312057
20.

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.

Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD.

J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S20-8. doi: 10.1097/JCP.0b013e318169d4ce.

PMID:
18334909
Items per page

Supplemental Content

Support Center